Pharma serv

According to 2024 - 2025 prescription data, it is revealed that over half of new-to-brand prescriptions were rejected, and only 29% were ultimately filled.

Non-coverage was the most common reason for rejection, often as a result of a "new-to-market block".

You can also learn how PharmaServ helps Lifescience brands identify key high-value Healthcare Practitioners ready with conversion intent.

Let's get you started on the right track to improve New-to-brand prescriptions (NBRx).

Schedule a discovery call today
https://calendly.com/pharmaserv/15min

Drugdiscovery